Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M

Grünenthal has agreed to acquire AstraZeneca's European rights to Nexium (esomeprazole) and the pharma giant’s rights to Vimovo® (naproxen/esomeprazole) worldwide except the U.S. and Japan for up to $922 million, the companies said today.The deal reflects both Grünenthal’s intent to expand its pain therapeutics business across multiple categories and territories worldwide—and AstraZeneca’s ongoing streamlining of its drug pipeline.This acquisition is the big